Beckman Coulter has announced that it will be combining Agencourt Bioscience and the newly acquired Cogenics to Beckman Coulter Genomics.
Beckman Coulter has announced that it will be combining Agencourt Bioscience and the newly acquired Cogenics to form Beckman Coulter Genomics. The new company is expected to offer researchers a single genomic services resource with expanded global capabilities.
"Through the creation of Beckman Coulter Genomics, we have successfully brought together the industry's leading genomic service providers to offer our customers the highest quality data and analysis," said Richard Creager, PhD, Beckman Coulter group vice president of immunoassay, molecular diagnostics and genomic services, in a statement.
Services currently available through the new company are reported to include sequencing, sample preparation, genotyping, gene expression, biological efficiency and safety testing, with support for all levels of regulatory compliance, including Clinical Laboratory Improvement Amendments (CLIA).
The new company has offices throughout North America and Europe.
For more information about Beckman Coulter Genomics visit www.beckmangenomics.com, www.agencourt.com and www.cogenics.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.